Simulations Plus’ (SLP) “Outperform” Rating Reiterated at William Blair

William Blair reiterated their outperform rating on shares of Simulations Plus (NASDAQ:SLP) in a report released on Tuesday,RTT News reports.

SLP has been the subject of several other research reports. Wall Street Zen upgraded Simulations Plus from a “sell” rating to a “hold” rating in a report on Monday, April 28th. KeyCorp raised their price objective on shares of Simulations Plus from $32.00 to $40.00 and gave the stock an “overweight” rating in a research report on Wednesday, April 16th. Two research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $50.00.

Simulations Plus Trading Up 0.9%

SLP stock opened at $27.79 on Tuesday. The stock has a 50-day moving average price of $30.56 and a two-hundred day moving average price of $30.37. The stock has a market cap of $558.88 million, a PE ratio of 69.48 and a beta of 1.10. Simulations Plus has a 1 year low of $23.01 and a 1 year high of $50.11.

Simulations Plus (NASDAQ:SLP) last released its earnings results on Thursday, April 3rd. The technology company reported $0.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.25 by $0.06. The firm had revenue of $22.43 million during the quarter, compared to analysts’ expectations of $21.93 million. Simulations Plus had a return on equity of 6.84% and a net margin of 10.97%. The company’s revenue was up 22.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.20 EPS. On average, analysts forecast that Simulations Plus will post 1.09 earnings per share for the current fiscal year.

Insider Activity at Simulations Plus

In other Simulations Plus news, Director Walter S. Woltosz sold 20,000 shares of the business’s stock in a transaction on Thursday, May 1st. The shares were sold at an average price of $33.51, for a total transaction of $670,200.00. Following the sale, the director now owns 3,344,157 shares of the company’s stock, valued at approximately $112,062,701.07. The trade was a 0.59% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 19.40% of the stock is currently owned by insiders.

Institutional Trading of Simulations Plus

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Stephens Inc. AR bought a new stake in shares of Simulations Plus in the fourth quarter worth $905,000. Principal Financial Group Inc. grew its stake in shares of Simulations Plus by 4.5% in the fourth quarter. Principal Financial Group Inc. now owns 91,177 shares of the technology company’s stock worth $2,543,000 after purchasing an additional 3,904 shares during the last quarter. Rice Hall James & Associates LLC grew its stake in shares of Simulations Plus by 19.4% in the fourth quarter. Rice Hall James & Associates LLC now owns 91,500 shares of the technology company’s stock worth $2,552,000 after purchasing an additional 14,871 shares during the last quarter. Olympiad Research LP bought a new stake in shares of Simulations Plus in the fourth quarter worth $211,000. Finally, Proficio Capital Partners LLC bought a new stake in shares of Simulations Plus in the fourth quarter worth $719,000. Institutional investors own 78.08% of the company’s stock.

Simulations Plus Company Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.